3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
1129
Carcinoma, Non-Small-Cell Lung
718
Neoplasms
546
Prostatic Neoplasms
505
Colorectal Neoplasms
439
Multiple Myeloma
338
Lung Neoplasms
310
Neoplasm Metastasis
289
Leukemia, Myeloid, Acute
263
Stomach Neoplasms
248
Carcinoma, Hepatocellular
246
Ovarian Neoplasms
225
Rectal Neoplasms
211
Colonic Neoplasms
204
Lymphoma, Follicular
200
Lymphoma
199
Leukemia
190
Uterine Cervical Neoplasms
181
Head and Neck Neoplasms
174
Pancreatic Neoplasms
172
Lymphoma, Non-Hodgkin
167
Leukemia, Lymphocytic, Chronic, B-Cell
166
Lymphoma, Large B-Cell, Diffuse
163
Recurrence
162
Melanoma
158
Precursor Cell Lymphoblastic Leukemia-Lymphoma
154
Squamous Cell Carcinoma of Head and Neck
147
Pain
141
Urinary Bladder Neoplasms
139
Brain Neoplasms
133
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Interventional
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA